The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Digital Trial Lecture – time and place
- First opponent: Associate professor Martin Magnusson, Lunds Universitet
- Second opponent: Professor Rune Wiseth, NTNU
- Third member and chair of the evaluation committee: Professor Anne Eskild, University of Oslo
Chair of the Defence
Professor Vegard Dahl, University of Oslo
Researcher Helge Røsjø, University of Oslo
Patients with acute dyspnea represent a medical emergency, frequently caused by heart failure (HF) or chronic obstructive pulmonary disease (COPD), conditions associated with significant mortality. With an aging population, the prevalence of HF will increase.
Several pathophysiological pathways are activated in HF and can be monitored by cardiovascular (CV) biomarkers. Novel biomarkers may therefore improve the management of patients with acute dyspnea. Hence, Mohammad Osman Pervez, MD, and colleagues have assessed the potential of three novel CV biomarkers in patients with dyspnea included in the ACE 2 Study.
In paper #1, tMR-proADM measured <24 h of admission was inferior to NT-proBNP to diagnose acute HF. However, elevated concentrations of MR-proADM were strongly associated with mortality after adjusting for established risk factors. In paper #2, we found MR-proANP to demonstrate similar diagnostic and prognostic accuracy as NT-proBNP in patients with acute dyspnea. In contrast to NT-proBNP, MR-proANP was also indpendently associated with mortality in patients with acute COPD. FGF23 is known to predict outcome in patients with chronic renal failure, a common comorbidity in patients with HF. We are the first to examine FGF23 in patients with acute dyspnea, regardless of their renal funtion. In paper #3, FGF23 measured <24 h of admission independently predicted poor outcome in adjusted risk models. However, FGF23 was inferior to NT-proBNP for diagnosing HF and for risk assessment in patients with HF.
In paper #4, we provide the rationale and methodology for the ACE 1950 Study which is a large community-acquired cohort. Dr. Pervez and co-workers examined 3706 participants with extensive phenotyping at the baseline visit, and are permitted follow these participants until year 2050.The ACE 1950 Study will generate new knowledge related to patients with dyspnea, and especially HF.
Contact the research support staff.